First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307

20260 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov NCT03594747.

Good health and well-being

Published in: Oncology and Therapy

Field-Weighted Citation Impact: 0.00